Results 11 to 20 of about 455 (134)

Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry. [PDF]

Arch Dermatol Res
AbstractSecukinumab is a fully human IgG1 antibody that selectively binds to and neutralizes the proinflammatory cytokine interleukin-17A. Secukinumab is an effective and well-tolerated treatment for plaque psoriasis. There is a limited real-word evidence for dose optimisation of secukinumab based on clinical response.
Papp KA, Gooderham M, Lynde C, Brassard D, Al-Mohammedi F, Prajapati VH, Delorme I, Albrecht L, Haydey R, Alam MS, Beecker J, Siddha S, Maguin M, Farag MS, Vieira A, Rihakova L, Langley RG.   +16 more
europepmc   +3 more sources

A Safe and Effective 7 Week Updosing Protocol for Bee and Wasp Venom Immunotherapy

Clinical and Experimental Allergy
Hymenoptera venom immunotherapy (VIT) is the only effective treatment to prevent systemic reactions (SR) and anaphylaxis from insect stings. The efficacy of VIT is well established, with success rates of 77%–84% for bee venom and 90%–95% for wasp venom [1, 2].
Shuaib Nasser
exaly   +4 more sources

Characterization of omalizumab updosing patterns and predictive factors in chronic spontaneous urticaria: A prospective multicentric observational study

Allergy: European Journal of Allergy and Clinical Immunology
Background: Limited information is available on the use of omalizumab (OMA) updosing since its introduction as a second-line therapy in chronic spontaneous urticaria (CSU) in 2014. Practical guidelines from health authorities are lacking, and the specific characteristics of patients requiring higher doses remain ...
Frédéric Dezoteux, Angele Soria, Guillaume Pierrard   +2 more
exaly   +5 more sources

Algorithms of Patient Selection for Allergen Immunotherapy. [PDF]

Allergy
Allergy, Volume 81, Issue 6, Page 2225-2229, June 2026.
Zieglmayer UP, Arasi S, Eiwegger T, Jakob T, Klimek L, Ollert M.   +5 more
europepmc   +2 more sources

Updosing of antihistamines to improve control of chronic urticaria

Indian Journal of Dermatology, Venereology and Leprology, 2010
Kiran Godse, Kiranv Godse
exaly   +3 more sources

Comment on “Children with chronic urticaria can be effectively controlled with updosing second-generation antihistamines” [PDF]

Journal of the American Academy of Dermatology, 2020
Anil Budania, Yashdeep Singh Pathania
exaly   +3 more sources

Real-life experience of efficacy and safety of bilastine in the refractory cases of chronic spontaneous urticaria and its effect on the quality of life of patients

Indian Journal of Dermatology, 2021
Introduction: Second-generation H1-antihistamines (SGAHs) are the mainstay of treatment of chronic spontaneous urticaria (CSU). Bilastine, newer non-sedating SGAHs, was recently introduced in India after the approval of the Drugs Controller General of ...
Abhishek De, Kiran Godse, Dhiraj Dhoot, Aarti Sarda   +3 more
doaj   +1 more source

Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria [PDF]

Journal of Allergy and Clinical Immunology, 2016
Andreas Dr Werner, Sabine Altrichter, Marcus Maurer   +2 more
exaly   +2 more sources

Omalizumab for the treatment of chronic spontaneous urticaria: association between body mass index and outcome

Dermatology Practical & Conceptual, 2022
Introduction: Omalizumab has been recently registered as a third-line therapy for chronic spontaneous urticaria. Objectives: In this study, we aimed to provide real life data by reporting our experience with omalizumab in the treatment of chronic ...
Irene Russo, Sara Cazzolla, Francesca Pampaloni, Mauro Alaibac   +3 more
doaj   +1 more source

Omalizumab Updosing for Better Disease Control in Chronic Spontaneous Urticaria Patients [PDF]

International Archives of Allergy and Immunology, 2018
The recommended dose of omalizumab for the treatment of chronic spontaneous urticaria (CSU) is 300 mg every 4 weeks, but there is no recommendation for patients who do not benefit from this dose. Our aim is to present the experiences on the use of doses of omalizumab higher than those recommended for CSU patients and to propose a protocol for updosing.
Emek Kocatürk, Gustavo Deza, Kübra Kızıltaç, Ana M. Giménez-Arnau   +3 more
openaire   +3 more sources